Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer.
Annals of nuclear medicine, vol.30, no.1, pp.60-7, 2016 (SCI-Expanded)
- Publication Type: Article / Article
- Volume: 30 Issue: 1
- Publication Date: 2016
- Doi Number: 10.1007/s12149-015-1031-1
- Journal Name: Annals of nuclear medicine
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.60-7
- Keywords: Thyroid carcinoma, Technetium-99m pertechnetate, Iodine-131, Remnant ablation, FOLLOW-UP, I-131 SCANS, MBQ I-131, CARCINOMA, PAPILLARY, MANAGEMENT, ABLATION, THERAPY, DISEASE, TC-99M-PERTECHNETATE
- Akdeniz University Affiliated: Yes
Abstract
Aim Postoperative scanning may help to identify patients with differentiated thyroid cancer (DTC); however, low dose I-131 can lead to stunning and suboptimal response to ablative therapy. The aim of this retrospective study is to compare postablative I-131 scintigraphy with post-thyroidectomy Tc-99m pertechnetate scintigraphy, serum thyroglobulin (Tg) and antithyroglobulin antibody (TgAb) levels in patients with DTC.